erythromycin has been researched along with Soft Tissue Neoplasms in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Baker, LH; Chugh, R; Griffith, KA; Leu, KM; Taylor, JM; Thomas, DG; Wagner, T; Worden, FP; Zalupski, MM | 1 |
Baker, LH; Bruno, R; Hirth, J; Schott, A; Strawderman, M; Watkins, PB | 1 |
2 trial(s) available for erythromycin and Soft Tissue Neoplasms
Article | Year |
---|---|
Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Erythromycin; Humans; Ifosfamide; Remission Induction; Sarcoma; Soft Tissue Neoplasms; Time Factors | 2007 |
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breath Tests; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Erythromycin; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Mixed Function Oxygenases; Orosomucoid; Paclitaxel; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2000 |